Lumos Pharma Inc

Lumos Pharma — FY2021 Earnings Presentation

10 slides from Lumos Pharma's earnings presentation, Mar 10, 2022

  1. Slide 1: Full Year 2021 Financial Results & Clinical Update

    1 Full Year 2021 Financial Results & Clinical Update March 10, 2022

  2. Slide 2: Forward Looking Statements

    2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All such statements contained in this presentation are forward-looking statements within the meaning of The Private Securities Litigation Reform

  3. Slide 3: Agenda

    3 Agenda • Lisa Miller, Senior Director of Investor Relations • Rick Hawkins, Chief Executive Officer & Chairman • Rick Hawkins, Chief Executive Officer & Chairman • John McKew, PhD, President & Chief Scientific Officer • David B. Karpf, MD, Chief Medical Officer • Lori Lawley, Chief Financial Offic

  4. Slide 4: New Plan for Interim Analyses for OraGrowtH210 and OraGrowtH212 Trials

    4 New Plan for Interim Analyses for OraGrowtH210 and OraGrowtH212 Trials Interim Analysis for Phase 2 OraGrowtH210 Trial • Interim analysis of data from 40 subjects at 6 months on therapy • 3 dose levels of oral LUM-201 vs standard dose of rhGH • Annualized height velocity (AHV) and safety data to b

  5. Slide 5: LUM-201 Program Pipeline

    5 LUM-201 Program Pipeline Study Pre-Clinical Phase 1 Phase 2 Phase 3 Status LUM-201 (Ibutamoren) In PGHD Phase 2 Ongoing Phase 2 trial: Interim analysis anticipated by year-end 2022 | Primary outcome data 2H2023 Long-term extension Proposed long-term extension study for OraGrowtH Trials PK/PD trial

  6. Slide 6: OraGrowtH210 Trial: Phase 2 Trial in PGHD

    6 OraGrowtH210 Trial: Phase 2 Trial in PGHD n = 20 Daily rhGH injection n = 20 LUM-201: 3.2 mg/kg/day n = 20 LUM-201: 1.6 mg/kg/day n = 20 LUM-201: 0.8 mg/kg/day • n = 80 • PEM(+) PGHD subjects • Inclusion: stim GH ≥ 5 ng/ml and baseline IGF-1 >30 ng/ml • rhGH treatment naïve • ~40 trial sites US &

  7. Slide 7: OraGrowtH212 Trial: Pharmacokinetic / Pharmacodynamic Trial in PGHD

    7 • n = up to 24 • Open-label study • PGHD patients • rhGH-treatment naïve • 12-month dosing • Single, specialized clinical site • Q10 minute GH sampling for 12 hours OraGrowtH212 Trial: Pharmacokinetic / Pharmacodynamic Trial in PGHD Primary Endpoints: • Assess LUM-201 effect on endogenous GH pulsa

  8. Slide 8: OraGrowtH213 Trial: Phase 2 Switch Trial in PGHD

    8 • n = up to 20 • PGHD subjects from rhGH treatment arm of OraGrowtH210 Trial after completion of 12 months on therapy • Open-label, multi-center switch study • LUM-201 treatment months 13-24 OraGrowtH213 Trial: Phase 2 Switch Trial in PGHD Primary Objectives: • Assess growth and safety of oral LUM

  9. Slide 9: Secure Cash Position

    9 Secure Cash Position Cash balance to support current operations through primary outcome data readouts for OraGrowtH210 and OraGrowtH212 Trials Metric Position Cash balance December 31, 2021 $94.8 million Cash use through 2022 $8.5 to $9.5 million per quarter Strong financial position Cash runway t

  10. Slide 10: Investment Highlights

    10 Investment Highlights PGHD = Pediatric Growth Hormone Deficiency * USA, Germany, France, Italy, Spain, UK, Japan (Grandview Research, Growth Hormone Market Forecast, 2019) Novel Oral Rare Disease Asset Pipeline in a Product Solid Financial Position • Novel oral therapeutic asset, LUM-201, for gro

Lumos Pharma — FY2021 Earnings Presentation on 6ix